These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22146228)

  • 1. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
    Bowles DW; Kessler ER; Jimeno A
    Drugs Today (Barc); 2011 Nov; 47(11):857-68. PubMed ID: 22146228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib use in renal cell carcinoma.
    Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW
    Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
    Grüllich C
    Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
    Fay AP; Albiges L; Bellmunt J
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cabozantinib: Mechanism of action, efficacy and indications].
    Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
    Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of c-MET Inhibitors in Cancer.
    Puccini A; Marín-Ramos NI; Bergamo F; Schirripa M; Lonardi S; Lenz HJ; Loupakis F; Battaglin F
    Drug Saf; 2019 Feb; 42(2):211-233. PubMed ID: 30649748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
    Pinto A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib in Thyroid Cancer.
    Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A
    Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.
    Grüllich C
    Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib: a review of its use in patients with medullary thyroid cancer.
    Hoy SM
    Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib as an emerging treatment for sarcoma.
    Schöffski P; Blay JY; Ray-Coquard I
    Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.
    Zhang X; Shao Y; Wang K
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1109-15. PubMed ID: 27181268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor.
    Markowitz JN; Fancher KM
    Pharmacotherapy; 2018 Mar; 38(3):357-369. PubMed ID: 29283440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib as a novel therapy for renal cell carcinoma.
    Vaishampayan U
    Curr Oncol Rep; 2013 Apr; 15(2):76-82. PubMed ID: 23292795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.